B7-H3, a member of the B7 family of immune regulators, is often overexpressed in cancers. In this manuscript, Scribner and colleagues disclose MGC018, an antibody-drug conjugate (ADC) targeting B7-H3. MGC018 carries a duocarmycin payload linked to the humanized IgG1/kapp. monoclonal antibody. Their ADC showed antitumor activity in a range of patient-derived xenografts, including triple-negative breast cancer, prostate cancer, and head and neck squamous cell carcinoma. Preclinical results in this First Disclosure support the clinical development of MGC018 in solid cancers.

There are many clinical and pathological similarities between human and canine mucosal melanomas. Two axes common to both species are the Ras/MAPK and PI3K/Akt/mTOR pathways. Wei and colleagues investigated the use of an MEK inhibitor (trametinib) previously investigated in canine models combined with the PI3K/mTOR inhibitor sapanisertib. The combined therapy reduced pS6/pERK, modified Bim/Bcl-xL expression, and limited tumor metastasis. Optimizing the dosage strategy required daily dose of trametinib and staggering...

You do not currently have access to this content.